Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Samuel Bourassa-Blanchette"'
Autor:
Samuel Bourassa-Blanchette, Marit M. Biesheuvel, John C. Lam, Alexander Kipp, Deirdre Church, Julie Carson, Bruce Dalton, Michael D. Parkins, Herman W. Barkema, Daniel B. Gregson
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Candidemia is increasing in frequency and is associated with high mortality. We sought to determine the burden of illness, the population it affects and its resistance profile in our region. Methods The Calgary Zone (CZ) provides
Externí odkaz:
https://doaj.org/article/9e0d0245b9bd499c81ddf442e8f817eb
Autor:
Greg Knoll, Michael Ong, Andrea Marie Ibrahim, Samuel Bourassa-Blanchette, Christina Canil, Todd Fairhead
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Background Nivolumab (Opdivo™) is a novel IgG4 subclass programmed death-1 (PD-1) inhibiting antibody that has demonstrated breakthrough-designation anti-tumor activity. To date, clinical trials of nivolumab and other checkpoint inhibitors have gen
Externí odkaz:
https://doaj.org/article/4eb72c8aff494b408e58dcc1074c8318
Publikováno v:
J Assoc Med Microbiol Infect Dis Can
Leprosy (Hansen’s disease) is caused by Mycobacterium leprae. It affects the skin and peripheral nerves. Incidence and prevalence are underestimated due to challenges in diagnosis and unfamiliarity with the disease in Canada. Untreated disease can
Autor:
Brian Hutton, Alexandria Bennett, Nicholas A Fergusson, Samuel Bourassa-Blanchette, D. William Cameron, Jason Tay, Juthaporn Cowan, Greg Knoll
Publikováno v:
Clinical transplantation. 33(6)
Polyvalent immunoglobulin is commonly used for desensitization and treatment of antibody-mediated rejection in kidney transplantation but its impact on other outcomes is not known. This systematic review investigated the impact of immunoglobulin prop
Autor:
Parul Tandon, Jeffrey D. McCurdy, Simon Parlow, Kirles Bishay, Samuel Bourassa-Blanchette, Scott A. Laurie
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 41(3)
Checkpoint inhibitors are a first-line therapy for advanced melanoma, though their use is limited by diarrhea and colitis. The aim of our study was to determine the risk of these toxicities associated with immunotherapy in advanced melanoma. Electron
Autor:
Donald William Cameron, Juthaporn Cowan, Greg Knoll, Samuel Bourassa-Blanchette, Jason Tay, Christopher Bredeson
Publikováno v:
Transplant infectious disease : an official journal of the Transplantation Society. 19(4)
Background Infection remains one of the most common transplant-related causes of death in patients undergoing transplantation. Secondary hypogammaglobulinemia (HGG) as a component of immune suppression and deficiency is associated with both solid org
Autor:
Donatella Tampieri, Maria Del Pilar Cortés Nino, Denise Klein, Kelvin Mok, Samuel Bourassa-Blanchette, Roberta La Piana
Publikováno v:
Interventional Neuroradiology. 19:329-338
We describe a case of brain cortical reorganization after embolization of a large right temporal arteriovenous malformation. A comprehensive imaging protocol, including functional magnetic resonance imaging (fMRI), cortical thickness analysis and 320
Autor:
Samuel Bourassa-Blanchette, Christina Canil, Andrea Marie Ibrahim, Greg Knoll, Todd Fairhead, Michael K. Ong
Publikováno v:
Journal for Immunotherapy of Cancer
Background Nivolumab (Opdivo™) is a novel IgG4 subclass programmed death-1 (PD-1) inhibiting antibody that has demonstrated breakthrough-designation anti-tumor activity. To date, clinical trials of nivolumab and other checkpoint inhibitors have gen
Publikováno v:
JMM Case Reports
Introduction: Rhizopus typically results in acute, aggressive and angioinvasive infection, particularly in immunosuppressed individuals. Risk factors include immunosuppression in haematologic malignancy, uncontrolled hyperglycemia, iron overload stat
Autor:
Parul Tandon, Scott A. Laurie, Samuel Bourassa-Blanchette, Kirles Bishay, Simon Parlow, Jeffrey D. McCurdy
Publikováno v:
Gastroenterology. 154:S-104